SrasV1, Ncbi, Merge, bibRecord, 002E20

Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity.

Identifieur interne : 002E20 ( Ncbi/Merge ); précédent : 002E19; suivant : 002E21

Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity.

Auteurs : Cheng-Wei Yang [République populaire de Chine] ; Yue-Zhi Lee [République populaire de Chine] ; Hsing-Yu Hsu [République populaire de Chine] ; Chuan Shih [République populaire de Chine] ; Yu-Sheng Chao [République populaire de Chine] ; Hwan-You Chang [République populaire de Chine] ; Shiow-Ju Lee [République populaire de Chine]

Source :

Scientific reports [ 2045-2322 ] ; 2017.

RBID : pubmed:28642467

Descripteurs français

KwdFr :
- ARN viral, Alcaloïdes (), Alcaloïdes (pharmacologie), Antiviraux (), Antiviraux (pharmacologie), Benzamides (pharmacologie), Coronavirus (), Coronavirus (physiologie), Facteur de transcription NF-kappa B (métabolisme), Indolizine (), Indolizine (pharmacologie), Infections à coronavirus (métabolisme), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Interactions hôte-pathogène, Kinase Janus-2 (métabolisme), Modèles biologiques, Phosphorylation, Phénanthrènes (), Phénanthrènes (pharmacologie), Réplication virale (), Transcription génétique, Transduction du signal ().
MESH :
- métabolisme : Facteur de transcription NF-kappa B, Infections à coronavirus, Kinase Janus-2.
- pharmacologie : Alcaloïdes, Antiviraux, Benzamides, Indolizine, Phénanthrènes.
- physiologie : Coronavirus.
- traitement médicamenteux : Infections à coronavirus.
- virologie : Infections à coronavirus.
- ARN viral, Alcaloïdes, Antiviraux, Coronavirus, Indolizine, Interactions hôte-pathogène, Modèles biologiques, Phosphorylation, Phénanthrènes, Réplication virale, Transcription génétique, Transduction du signal.

English descriptors

KwdEn :
- Alkaloids (chemistry), Alkaloids (pharmacology), Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Benzamides (pharmacology), Coronavirus (drug effects), Coronavirus (physiology), Coronavirus Infections (drug therapy), Coronavirus Infections (metabolism), Coronavirus Infections (virology), Host-Pathogen Interactions, Indolizines (chemistry), Indolizines (pharmacology), Janus Kinase 2 (metabolism), Models, Biological, NF-kappa B (metabolism), Phenanthrenes (chemistry), Phenanthrenes (pharmacology), Phosphorylation, RNA, Viral, Signal Transduction (drug effects), Transcription, Genetic, Virus Replication (drug effects).
MESH :
- chemical , chemistry : Alkaloids, Antiviral Agents, Indolizines, Phenanthrenes.
- chemical , metabolism : Janus Kinase 2, NF-kappa B.
- chemical , pharmacology : Alkaloids, Antiviral Agents, Benzamides, Indolizines, Phenanthrenes.
- drug effects : Coronavirus, Signal Transduction, Virus Replication.
- drug therapy : Coronavirus Infections.
- metabolism : Coronavirus Infections.
- physiology : Coronavirus.
- virology : Coronavirus Infections.
- Host-Pathogen Interactions, Models, Biological, Phosphorylation, RNA, Viral, Transcription, Genetic.

Abstract

Tylophorine-based compounds exert broad spectral, potent inhibition of coronaviruses. NF-κB activation is a common pro-inflammatory response of host cells to viral infection. The aims of this study were to (i) find an effective combination treatment for coronaviral infections through targeting of the virus per se and cellular NF-κB activity; and (ii) to study the underling mechanisms. We found that tylophorine-based compounds target the TGEV viral RNA and effectively inhibit TGEV replication. NF-κB inhibition also leads to anti-TGEV replication. NF-κB activation induced by TGEV infection was found to be associated with two convergent pathways, IKK-2_IκBα/p65 and JAK2 mediated p65 phosphorylation, in swine testicular cells. JAK2 inhibition either by CYT387 (a JAK family inhibitor) or by silencing JAK2-expression revealed a dominant JAK2 mediated p65 phosphorylation pathway for NF-κB activation and resulted in NF-κB inhibition, which overrode the IκBα regulation via the IKK-2. Finally, tylophorine-based compounds work cooperatively with CYT387 to impart comprehensive anti-TGEV activities. The combination treatment, wherein a tylophorine compound targets TGEV and a JAK2 inhibitor blocks the alternative dominant NF-κB activation mediated by JAK2, is more effective and comprehensive than either one alone and constitutes a feasible approach for the treatment of SARS-CoV or MERS-CoV.

DOI: 10.1038/s41598-017-04203-9
PubMed: 28642467

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000B08
to stream PubMed, to step Curation: 000B08
to stream PubMed, to step Checkpoint: 000A59

Links to Exploration step

pubmed:28642467

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity.</title>
<author><name sortKey="Yang, Cheng Wei" sort="Yang, Cheng Wei" uniqKey="Yang C" first="Cheng-Wei" last="Yang">Cheng-Wei Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lee, Yue Zhi" sort="Lee, Yue Zhi" uniqKey="Lee Y" first="Yue-Zhi" last="Lee">Yue-Zhi Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hsu, Hsing Yu" sort="Hsu, Hsing Yu" uniqKey="Hsu H" first="Hsing-Yu" last="Hsu">Hsing-Yu Hsu</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shih, Chuan" sort="Shih, Chuan" uniqKey="Shih C" first="Chuan" last="Shih">Chuan Shih</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chao, Yu Sheng" sort="Chao, Yu Sheng" uniqKey="Chao Y" first="Yu-Sheng" last="Chao">Yu-Sheng Chao</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chang, Hwan You" sort="Chang, Hwan You" uniqKey="Chang H" first="Hwan-You" last="Chang">Hwan-You Chang</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, 30013, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, 30013, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lee, Shiow Ju" sort="Lee, Shiow Ju" uniqKey="Lee S" first="Shiow-Ju" last="Lee">Shiow-Ju Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC. slee@nhri.org.tw.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28642467</idno>
<idno type="pmid">28642467</idno>
<idno type="doi">10.1038/s41598-017-04203-9</idno>
<idno type="wicri:Area/PubMed/Corpus">000B08</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B08</idno>
<idno type="wicri:Area/PubMed/Curation">000B08</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B08</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000A59</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A59</idno>
<idno type="wicri:Area/Ncbi/Merge">002E20</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity.</title>
<author><name sortKey="Yang, Cheng Wei" sort="Yang, Cheng Wei" uniqKey="Yang C" first="Cheng-Wei" last="Yang">Cheng-Wei Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lee, Yue Zhi" sort="Lee, Yue Zhi" uniqKey="Lee Y" first="Yue-Zhi" last="Lee">Yue-Zhi Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hsu, Hsing Yu" sort="Hsu, Hsing Yu" uniqKey="Hsu H" first="Hsing-Yu" last="Hsu">Hsing-Yu Hsu</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shih, Chuan" sort="Shih, Chuan" uniqKey="Shih C" first="Chuan" last="Shih">Chuan Shih</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chao, Yu Sheng" sort="Chao, Yu Sheng" uniqKey="Chao Y" first="Yu-Sheng" last="Chao">Yu-Sheng Chao</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chang, Hwan You" sort="Chang, Hwan You" uniqKey="Chang H" first="Hwan-You" last="Chang">Hwan-You Chang</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, 30013, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, 30013, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lee, Shiow Ju" sort="Lee, Shiow Ju" uniqKey="Lee S" first="Shiow-Ju" last="Lee">Shiow-Ju Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC. slee@nhri.org.tw.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Scientific reports</title>
<idno type="eISSN">2045-2322</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alkaloids (chemistry)</term>
<term>Alkaloids (pharmacology)</term>
<term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Benzamides (pharmacology)</term>
<term>Coronavirus (drug effects)</term>
<term>Coronavirus (physiology)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (metabolism)</term>
<term>Coronavirus Infections (virology)</term>
<term>Host-Pathogen Interactions</term>
<term>Indolizines (chemistry)</term>
<term>Indolizines (pharmacology)</term>
<term>Janus Kinase 2 (metabolism)</term>
<term>Models, Biological</term>
<term>NF-kappa B (metabolism)</term>
<term>Phenanthrenes (chemistry)</term>
<term>Phenanthrenes (pharmacology)</term>
<term>Phosphorylation</term>
<term>RNA, Viral</term>
<term>Signal Transduction (drug effects)</term>
<term>Transcription, Genetic</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral</term>
<term>Alcaloïdes ()</term>
<term>Alcaloïdes (pharmacologie)</term>
<term>Antiviraux ()</term>
<term>Antiviraux (pharmacologie)</term>
<term>Benzamides (pharmacologie)</term>
<term>Coronavirus ()</term>
<term>Coronavirus (physiologie)</term>
<term>Facteur de transcription NF-kappa B (métabolisme)</term>
<term>Indolizine ()</term>
<term>Indolizine (pharmacologie)</term>
<term>Infections à coronavirus (métabolisme)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Interactions hôte-pathogène</term>
<term>Kinase Janus-2 (métabolisme)</term>
<term>Modèles biologiques</term>
<term>Phosphorylation</term>
<term>Phénanthrènes ()</term>
<term>Phénanthrènes (pharmacologie)</term>
<term>Réplication virale ()</term>
<term>Transcription génétique</term>
<term>Transduction du signal ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Alkaloids</term>
<term>Antiviral Agents</term>
<term>Indolizines</term>
<term>Phenanthrenes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Janus Kinase 2</term>
<term>NF-kappa B</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Alkaloids</term>
<term>Antiviral Agents</term>
<term>Benzamides</term>
<term>Indolizines</term>
<term>Phenanthrenes</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term>
<term>Signal Transduction</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Facteur de transcription NF-kappa B</term>
<term>Infections à coronavirus</term>
<term>Kinase Janus-2</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Alcaloïdes</term>
<term>Antiviraux</term>
<term>Benzamides</term>
<term>Indolizine</term>
<term>Phénanthrènes</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Host-Pathogen Interactions</term>
<term>Models, Biological</term>
<term>Phosphorylation</term>
<term>RNA, Viral</term>
<term>Transcription, Genetic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>ARN viral</term>
<term>Alcaloïdes</term>
<term>Antiviraux</term>
<term>Coronavirus</term>
<term>Indolizine</term>
<term>Interactions hôte-pathogène</term>
<term>Modèles biologiques</term>
<term>Phosphorylation</term>
<term>Phénanthrènes</term>
<term>Réplication virale</term>
<term>Transcription génétique</term>
<term>Transduction du signal</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Tylophorine-based compounds exert broad spectral, potent inhibition of coronaviruses. NF-κB activation is a common pro-inflammatory response of host cells to viral infection. The aims of this study were to (i) find an effective combination treatment for coronaviral infections through targeting of the virus per se and cellular NF-κB activity; and (ii) to study the underling mechanisms. We found that tylophorine-based compounds target the TGEV viral RNA and effectively inhibit TGEV replication. NF-κB inhibition also leads to anti-TGEV replication. NF-κB activation induced by TGEV infection was found to be associated with two convergent pathways, IKK-2_IκBα/p65 and JAK2 mediated p65 phosphorylation, in swine testicular cells. JAK2 inhibition either by CYT387 (a JAK family inhibitor) or by silencing JAK2-expression revealed a dominant JAK2 mediated p65 phosphorylation pathway for NF-κB activation and resulted in NF-κB inhibition, which overrode the IκBα regulation via the IKK-2. Finally, tylophorine-based compounds work cooperatively with CYT387 to impart comprehensive anti-TGEV activities. The combination treatment, wherein a tylophorine compound targets TGEV and a JAK2 inhibitor blocks the alternative dominant NF-κB activation mediated by JAK2, is more effective and comprehensive than either one alone and constitutes a feasible approach for the treatment of SARS-CoV or MERS-CoV.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28642467</PMID>
<DateCompleted><Year>2018</Year>
<Month>12</Month>
<Day>31</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>01</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>7</Volume>
<Issue>1</Issue>
<PubDate><Year>2017</Year>
<Month>06</Month>
<Day>22</Day>
</PubDate>
</JournalIssue>
<Title>Scientific reports</Title>
<ISOAbbreviation>Sci Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity.</ArticleTitle>
<Pagination><MedlinePgn>4105</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-017-04203-9</ELocationID>
<Abstract><AbstractText>Tylophorine-based compounds exert broad spectral, potent inhibition of coronaviruses. NF-κB activation is a common pro-inflammatory response of host cells to viral infection. The aims of this study were to (i) find an effective combination treatment for coronaviral infections through targeting of the virus per se and cellular NF-κB activity; and (ii) to study the underling mechanisms. We found that tylophorine-based compounds target the TGEV viral RNA and effectively inhibit TGEV replication. NF-κB inhibition also leads to anti-TGEV replication. NF-κB activation induced by TGEV infection was found to be associated with two convergent pathways, IKK-2_IκBα/p65 and JAK2 mediated p65 phosphorylation, in swine testicular cells. JAK2 inhibition either by CYT387 (a JAK family inhibitor) or by silencing JAK2-expression revealed a dominant JAK2 mediated p65 phosphorylation pathway for NF-κB activation and resulted in NF-κB inhibition, which overrode the IκBα regulation via the IKK-2. Finally, tylophorine-based compounds work cooperatively with CYT387 to impart comprehensive anti-TGEV activities. The combination treatment, wherein a tylophorine compound targets TGEV and a JAK2 inhibitor blocks the alternative dominant NF-κB activation mediated by JAK2, is more effective and comprehensive than either one alone and constitutes a feasible approach for the treatment of SARS-CoV or MERS-CoV.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Cheng-Wei</ForeName>
<Initials>CW</Initials>
<AffiliationInfo><Affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Yue-Zhi</ForeName>
<Initials>YZ</Initials>
<AffiliationInfo><Affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hsu</LastName>
<ForeName>Hsing-Yu</ForeName>
<Initials>HY</Initials>
<AffiliationInfo><Affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shih</LastName>
<ForeName>Chuan</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chao</LastName>
<ForeName>Yu-Sheng</ForeName>
<Initials>YS</Initials>
<AffiliationInfo><Affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chang</LastName>
<ForeName>Hwan-You</ForeName>
<Initials>HY</Initials>
<AffiliationInfo><Affiliation>Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, 30013, Taiwan, ROC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Shiow-Ju</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo><Affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, 35053, Taiwan, ROC. slee@nhri.org.tw.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>06</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Sci Rep</MedlineTA>
<NlmUniqueID>101563288</NlmUniqueID>
<ISSNLinking>2045-2322</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000470">Alkaloids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007212">Indolizines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010616">Phenanthrenes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>76145IS906</RegistryNumber>
<NameOfSubstance UI="C492919">N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D053614">Janus Kinase 2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O41630Y8V3</RegistryNumber>
<NameOfSubstance UI="C004218">tylophorine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000470" MajorTopicYN="N">Alkaloids</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007212" MajorTopicYN="N">Indolizines</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053614" MajorTopicYN="N">Janus Kinase 2</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010616" MajorTopicYN="N">Phenanthrenes</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>01</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>05</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>6</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>6</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28642467</ArticleId>
<ArticleId IdType="doi">10.1038/s41598-017-04203-9</ArticleId>
<ArticleId IdType="pii">10.1038/s41598-017-04203-9</ArticleId>
<ArticleId IdType="pmc">PMC5481340</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Viruses. 2014 Aug 07;6(8):2991-3018</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25105276</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Carcinogenesis. 2013 Jun;34(6):1304-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23385061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2010 Nov;88(2):160-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20727913</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Pulm Med. 2014 May;20(3):233-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24626235</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell Biol. 2007 Mar;27(6):2324-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17210633</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 2006 Dec 22;580(30):6807-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17141229</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Jan;88(2):913-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24198408</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2001 Jan;107(2):143-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11160127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2013 Dec;11(12):836-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24217413</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Prog Nucleic Acid Res Mol Biol. 2002;72:223-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12206453</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2015 Jan;235(2):185-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25270030</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 2005;287:1-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15609507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Ther Pat. 2009 Mar;19(3):357-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19449500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncotarget. 2015 Feb 10;6(4):2148-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25669982</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Appl Pharmacol. 2017 Apr 23;:null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28438630</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15779-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18840688</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Jul;84(13):6472-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20427526</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Rev. 2015 Apr;28(2):465-522</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25810418</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Life Sci. 2005 Jul;62(13):1409-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15924259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1998 Jun;72(6):4918-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9573259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer. 2013 Aug 02;12:86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23915189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1988 Nov;62(11):4280-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2845140</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1988 Nov;62(11):4288-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2845141</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2006 Oct 30;25(51):6844-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17072332</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Protein Cell. 2013 Dec;4(12):951-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24318862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2012 Dec 13;55(23):10363-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23167614</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiol Mol Biol Rev. 2005 Dec;69(4):635-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16339739</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Ther Pat. 2009 Apr;19(4):415-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19441924</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2007 Nov;51(11):3924-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17709464</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Yang, Cheng Wei" sort="Yang, Cheng Wei" uniqKey="Yang C" first="Cheng-Wei" last="Yang">Cheng-Wei Yang</name>
</noRegion>
<name sortKey="Chang, Hwan You" sort="Chang, Hwan You" uniqKey="Chang H" first="Hwan-You" last="Chang">Hwan-You Chang</name>
<name sortKey="Chao, Yu Sheng" sort="Chao, Yu Sheng" uniqKey="Chao Y" first="Yu-Sheng" last="Chao">Yu-Sheng Chao</name>
<name sortKey="Hsu, Hsing Yu" sort="Hsu, Hsing Yu" uniqKey="Hsu H" first="Hsing-Yu" last="Hsu">Hsing-Yu Hsu</name>
<name sortKey="Lee, Shiow Ju" sort="Lee, Shiow Ju" uniqKey="Lee S" first="Shiow-Ju" last="Lee">Shiow-Ju Lee</name>
<name sortKey="Lee, Yue Zhi" sort="Lee, Yue Zhi" uniqKey="Lee Y" first="Yue-Zhi" last="Lee">Yue-Zhi Lee</name>
<name sortKey="Shih, Chuan" sort="Shih, Chuan" uniqKey="Shih C" first="Chuan" last="Shih">Chuan Shih</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E20 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002E20 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:28642467
   |texte=   Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:28642467" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity.

Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki